Literature DB >> 3012054

Use of digoxin in infants and children, with specific emphasis on dosage.

M K Park.   

Abstract

The foregoing discussion leads to several general conclusions regarding the use of digoxin in the pediatric patient. First, pharmacokinetic studies indicate that somewhat higher doses are required in the infant to attain the same serum levels as in the adult. Important sources for this difference appear to be more rapid body clearance of digoxin and larger volume of distribution in the infant. Second, higher serum digoxin levels are not indicated on the basis of decreased myocardial uptake of digoxin in the infant. Tissue uptake of digoxin, as indicated by myocardium/serum digoxin ratios, is higher in infants and children than in adults. Third, according to results of animal studies, the inotropic sensitivity to digoxin in the young is probably greater--certainly not less--than in the adult. This is opposite to a commonly held view that the immature heart is less sensitive to cardiac glycosides and therefore requires higher serum levels for a therapeutic effect. Rather, the infant has decreased sensitivity of the conduction system to digitalis toxicity, and healthy myocardium less prone to arrhythmia than the adult. Therefore the infant may tolerate, but does not require, higher serum levels of digoxin. Fourth, high levels of serum digoxin (greater than 2 ng/ml) are not associated with greater inotropic effects in the pediatric patient. The higher dosages of digoxin are, instead, associated with greater frequency of toxic effects, especially in infants receiving concomitant diuretic therapy. Therefore, a digoxin dosage recommendation is presented, that will result in mean serum digoxin levels of 1.1 to 1.7 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012054     DOI: 10.1016/s0022-3476(86)80919-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 2.  Digitalis toxicity in infancy and childhood.

Authors:  S Singh
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

Review 3.  Management of Supraventricular Tachycardia in Infants.

Authors:  Chalese Richardson; Eric S Silver
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 4.  Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.

Authors:  C Steinberg; D A Notterman
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 5.  Does digoxin have a place in the treatment of the child with congenital heart disease?

Authors:  A N Redington; J S Carvalho; E A Shinebourne
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

6.  Digoxin in management of heart failure in children: Should it be continued or relegated to the history books?

Authors:  Shreepal Jain; Balu Vaidyanathan
Journal:  Ann Pediatr Cardiol       Date:  2009-07

7.  Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt.

Authors:  Soham Dasgupta; Ashraf M Aly; Sunil K Jain
Journal:  AJP Rep       Date:  2015-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.